Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
InQu Bone Graft Extender and Substitute is a biosynthetic bone graft material composed of PLGA (poly(lactic-co-glycolic acid)) and hyaluronic acid. It is often used in combination with BMAC (Bone Marrow Aspirate Concentrate) in orthopedic procedures, particularly spinal fusion surgeries. InQu provides a biopolymer scaffold with a tailored resorption profile and a cell-friendly microenvironment. Studies have shown fusion rates of up to 94% with InQu, outperforming traditional synthetics. It partners with the body's natural healing process to form bone in a shorter period without inciting a negative immune response. Isto Biologics manufactures InQu, and its use is often paired with their BMAC harvesting and concentration systems like CellPoint and Magellan.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on InQu Bone Graft Extender and Substitute + BMAC.